BMY logo Bristol-Myers Squibb Company +
Bristol-Myers Squibb Company
+

Bristol-Myers Squibb Company (BMY) Business News

Track Bristol-Myers Squibb Company in real time with a live news feed covering Bristol-Myers Squibb Company stock news, official press releases, company announcements, and an archive of historical Bristol-Myers Squibb Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
2:54 AM | Saturday | May 16, 2026 Seeking Alpha

10 Sector Evaluation High Yield 4.5%+ Winners To Buy

News Thumbnail
2:54 AM | Saturday | May 16, 2026 Seeking Alpha

10 Sector Evaluation High Yield 4.5%+ Winners To Buy

News Thumbnail
11:04 AM | Friday | May 15, 2026 CNBC

Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration

News Thumbnail
8:30 AM | Thursday | May 14, 2026 Business Wire

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

News Thumbnail
7:28 AM | Tuesday | May 12, 2026 GuruFocus

Is BMY Undervalued? DCF Says Worth $74

News Thumbnail
2:35 AM | Tuesday | May 12, 2026 WSJ

Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up

News Thumbnail
12:27 AM | Tuesday | May 12, 2026 PRNewsWire

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

News Thumbnail
12:19 AM | Tuesday | May 12, 2026 Reuters

China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln

News Thumbnail
9:15 PM | Monday | May 11, 2026 The Motley Fool

Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.

News Thumbnail
4:07 AM | Sunday | May 10, 2026 MarketBeat

Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting

News Thumbnail
6:59 AM | Friday | May 8, 2026 Business Wire

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

News Thumbnail

10 Sector Evaluation High Yield 4.5%+ Winners To Buy

Seeking Alpha

2:54 AM | Saturday | May 16, 2026

news photo
Loading...

Rose's Income Garden portfolio targets high-yield, quality dividend stocks across 10 sectors, emphasizing value and credit quality. Current high-yield sector picks include MO, BMY, AES, VZ, GPC, and VICI, each with yields above 4.5% and favorable valuation or growth profiles. RIG's forward yield exceeds 6.09%, with YTD performance at 8.
39%, outpacing SPY's 0.99% yield and focusing on undervalued dividend payers.

Read full article redirect
2:54 AM | Saturday | May 16, 2026

10 Sector Evaluation High Yield 4.5%+ Winners To Buy

Seeking Alpha

Rose's Income Garden portfolio targets high-yield, quality dividend stocks across 10 sectors, emphasizing value and credit quality. Current high-yield sector picks include MO, BMY, AES, VZ, GPC, and VICI, each with yields above 4.5% and favorable valuation or growth profiles. RIG's forward yield exceeds 6.09%, with YTD performance at 8.
39%, outpacing SPY's 0.99% yield and focusing on undervalued dividend payers.

Read full article arrow
News Thumbnail
2:54 AM | Saturday | May 16, 2026

10 Sector Evaluation High Yield 4.5%+ Winners To Buy

Seeking Alpha

Rose's Income Garden portfolio targets high-yield, quality dividend stocks across 10 sectors, emphasizing value and credit quality. Current high-yield sector picks include MO, BMY, AES, VZ, GPC, and VICI, each with yields above 4.5% and favorable valuation or growth profiles. RIG's forward yield exceeds 6.09%, with YTD performance at 8.
39%, outpacing SPY's 0.99% yield and focusing on undervalued dividend payers.

Read full article arrow
News Thumbnail
11:04 AM | Friday | May 15, 2026

Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration

CNBC

Bristol Myers Squibb this week announced a partnership with Hengrui Pharma to develop drugs together. American and European biopharmaceutical companies are increasingly looking to China for their next blockbusters.

Read full article arrow
News Thumbnail
8:30 AM | Thursday | May 14, 2026

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

Business Wire

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs. With Lens, Tempus' AI-enabled analytical pl.

Read full article arrow
News Thumbnail
7:28 AM | Tuesday | May 12, 2026

Is BMY Undervalued? DCF Says Worth $74

GuruFocus

On May 12, 2026, we delve into the DCF analysis for Bristol-Myers Squibb Co (BMY), a company currently trading at $55.67. The stock has experienced a mixed perf

Read full article arrow
News Thumbnail
2:35 AM | Tuesday | May 12, 2026

Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up

WSJ

U.S. pharmaceutical giant Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals, in a deal that could worth more than $15 billion.

Read full article arrow
News Thumbnail
12:27 AM | Tuesday | May 12, 2026

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

PRNewsWire

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreements include 13 programs with the potential to address significant unmet patient needs and support long ‑ term growth SHANGHAI and PRINCETON, N.J., May 12, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui") (600276.SH; 01276.HK) and Bristol Myers Squibb ("BMS") today announced the companies have entered into global strategic collaboration and license agreements to advance a portfolio of 13 early stage programs in oncology, hematology and immunology, with the goal of accelerating discovery and development of innovative medicines for the benefit of patients worldwide.

Read full article arrow
News Thumbnail
12:19 AM | Tuesday | May 12, 2026

China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln

Reuters

China's Jiangsu ​Hengrui Pharmaceuticals ‌said on Tuesday ​it ​has struck global ⁠strategic collaboration ​and ​licensing deal with U.S. drugmaker ​Bristol ​Myers Squibb to ‌develop ⁠13 early‑stage oncology, hematology ​and ​immunology ⁠programmes, with ​potential ​milestone ⁠payments of up ⁠to $15.2 ​billion.

Read full article arrow
News Thumbnail
9:15 PM | Monday | May 11, 2026

Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.

The Motley Fool

Bristol Myers Squibb has faced patent cliffs in recent years and will face more in the next few years. The company's portfolio of newer drugs, along with its deep pipeline, can help it overcome this headwind.

Read full article arrow
News Thumbnail
4:07 AM | Sunday | May 10, 2026

Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting

MarketBeat

Bristol Myers Squibb NYSE: BMY used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives, while shareholders approved all management proposals and rejected a proposal to require an independent board chair.

Read full article arrow
News Thumbnail
6:59 AM | Friday | May 8, 2026

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults.

Read full article arrow
News Thumbnail